The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2019

Filed:

Jan. 11, 2017
Applicants:

National University Corporation Chiba University, Chiba-shi, Chiba, JP;

Eisai R&d Management Co., Ltd., Bunkyo-ku, Tokyo, JP;

Inventors:

Toshinori Nakayama, Chiba, JP;

Motoko Kimura, Chiba, JP;

Koji Hayashizaki, Chiba, JP;

Toshifumi Hirayama, Kobe, JP;

Jungo Kakuta, Kobe, JP;

Yoshimasa Sakamoto, Kobe, JP;

Ryu Gejima, Kobe, JP;

Daisuke Tokita, Kobe, JP;

Kenzo Muramoto, Kobe, JP;

Toshio Imai, Kobe, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61P 37/08 (2006.01); A61P 37/02 (2006.01); A61P 35/00 (2006.01); A61P 1/00 (2006.01); C07K 16/18 (2006.01); C07K 16/46 (2006.01); A61P 11/00 (2006.01); A61P 1/04 (2006.01); C07K 16/28 (2006.01); C07K 14/47 (2006.01); C12N 15/09 (2006.01);
U.S. Cl.
CPC ...
C07K 16/46 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 1/04 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/08 (2018.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 14/4716 (2013.01); C12N 15/09 (2013.01);
Abstract

The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.


Find Patent Forward Citations

Loading…